trending Market Intelligence /marketintelligence/en/news-insights/trending/wDobFw7lXOJzeYFGDIXTBw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merck to cut 500 US jobs; Pa. workers to be hit hardest

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Merck to cut 500 US jobs; Pa. workers to be hit hardest

Merck & Co. Inc. plans to cut 500 sales and headquarters jobs in the U.S. by early January 2020, mainly affecting those working out of Montgomery County, Pa., according to a Worker Adjustment and Retraining Notification letter filed with the state.

The letter said the cuts would be effective Jan. 3, 2020, and would affect not only those in the company's Upper Gwynedd, Pa., offices but also those working remotely outside of the state.

Pamela Eisele, a representative from Merck, told S&P Global Market Intelligence in an email that the layoffs are related to ongoing restructuring to focus on oncology research and development. The company's cancer drug Keytruda was the third best-selling drug in the world in 2018, pulling in $7.2 billion that year compared with $3.8 billion in 2017.

"This is not a new restructuring effort," Eisele said. "These changes are part of ongoing company-wide efforts to sharpen Merck's focus on innovative research and development that addresses significant unmet medical needs and on our best opportunities for growth."

Affected employees can apply to open positions elsewhere at Merck, Eisele said, and those not placed will be offered a severance package.